



## Château Haut-Brion 2015 Discount to other 100 Point WA Wines Creates Opportunity

- Château Haut-Brion is, according to *Wine Advocate*, the highest quality First Growth, in that it has the **most 100-point scores** since 1982.

100 Point Wines from Wine Advocate (not including ranges) 1982 - 2018					
	Haut-Brion	Lafite	Latour	Margaux	Mouton-Rothschild
Number of 100 Point Wines	<b>6</b>	1	5	2	3

- Of the six 100 point modern Haut-Brions, the **2015 is the cheapest and most attractive**.
- The Haut-Brion 1989 provides the benchmark for 100-point Haut-Brions, trading at **HK\$85,000** (6x75cl).
- We believe that both the Haut-Brion 2015 and Haut-Brion 1989 will both rise with inflation, as they are strictly fixed (indeed declining) in supply. The 1989 is 26 years older than the 2015, and the relative pricing of the two implies that the **2015 will rise at 4.8% + inflation rate** for the next 30 years. This is an excellent long-term, inflation-protected, return.
- Drinking window on Château Haut-Brion 2015 is to **2064**, making this an extraordinarily long-dated asset.
- 3 cases of Château Haut-Brion 2015 (6x75cl) offered at **HK\$24,910** and 1 case of Château Haut-Brion 2015 (12x75cl) at **HK\$48,970**.
- Stock is in investment grade condition in United Kingdom.
- Delivery to storage account in around 14 days.

### Haut-Brion 2015 –Discount to Other 100 Point Wine Advocate Wines

Haut-Brion 100 Point Wines and Prices					
Year	2015	2010	2009	2005	1989
Score	100 (WA)	100 (WA)	100 (WA)	100 (WA)	100 (WA)
Price	HK\$24,910	HK\$35,000	HK\$31,500	HK\$36,000	HK\$85,000
<b>2015 Discount</b>	-	-40.5%	-26.5%	-44.5%	-241.2%

## IMPORTANT NOTICE

This report has been issued or approved for issue by an entity forming part of Cru (as defined below) and has been forwarded to you solely for your information and should not be considered as an offer or solicitation of an offer to sell, buy or subscribe to any securities or any derivative instrument or any other rights pertaining thereto ("financial instruments"). This report is intended for use by professional or business investors only. This report may not be reproduced without the consent of Cru.

The information and opinions expressed in this report have been compiled from sources believed to be reliable, but, neither Cru, nor any of its directors, officers, or employees accepts liability from any loss arising from the use hereof or makes any representations as to its accuracy and completeness. Any opinions, forecasts or estimates herein constitute a judgement as at the date of this report. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or estimates. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. This information is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the product or products mentioned. Cru is not agreeing to nor is it required to update the opinions, forecasts or estimates contained herein.

The value of any products mentioned in this report can fall as well as rise. Foreign currency denominated products are subject to fluctuations in exchange rates that may have a positive or adverse effect on the value, price or income of such products.

This report does not have regard to the specific instrument objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any products or investment strategies discussed in this report.

Cru (or its directors, officers or employees) may, to the extent permitted by law, own or have a position in the products of any company or related company or products referred to herein, and may add to or dispose of any such position or may make a market or act as a principal in any transaction in such products. Directors of Cru may also be directors of any of the companies mentioned in this report. Cru (or its directors, officers or employees) may, to the extent permitted by law, act upon or use the information or opinions presented herein, or research or analysis on which they are based prior to the material being published. Cru may have issued other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them.

For the purposes of this disclaimer, "Cru" shall mean: (i) Cru London Limited; (ii) Cru Asia Limited and (iii) from time to time, in relation to Cru London Limited and/or Cru Asia Limited, the ultimate holding company of that entity, a subsidiary (or a subsidiary of a subsidiary) of that entity, a holding company of that entity or any other subsidiary of that holding company, and any affiliated entity of any such entities.

This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of an entity within Cru. Products referred to in this research report may not be eligible for sale in those jurisdictions where an entity within Cru is not authorised or permitted by local law to do so. In particular, Cru does not allow the redistribution of this report to non-professional investors or persons outside the jurisdictions referred to above and Cru cannot be held responsible in any way for third parties who effect such redistribution or recipients thereof. © 2019.